Medtronic (NYSE:MDT) announced today that it received FDA approval for its SenSight directional lead system used in deep brain stimulation therapy.
Fridley, Minn.–based Medtronic designed the SenSight directional lead system for DBS therapy to combine directionality and sensing to allow physicians to deliver precise, patient-specific DBS therapy for treating some symptoms associated with movement disorders including Parkinson’s disease, dystonia and essential tremor and medically refractory epilepsy, according to a news release.
The company touts SenSight as the first directional, sensing-enabled lead designed to improve the detection of local field potentials (LFPs). It’s possible to pair the SenSight leads with the Percept PC device to expand on Medtronic’s BrianSense technology to allow for the capturing and recording of enhanced directional LFP information from the implanted lead.
Multi-disciplinary teams at the University of Florida performed the first implants of the SenSight directional lead systems early on this month, with the company set to initiate the full U.S. launch following today’s announcement. SenSight also received CE mark and fully launched in Western Europe in March 2021.
“We are excited to see the clinical benefits that the new SenSight directional lead system will provide to patients and physicians in the U.S.,” Medtronic VP & GM of brain modulation Mike Daly said in the release. “For over 25 years, Medtronic has driven discoveries and advancements in DBS therapy and we look forward to continuing to deliver meaningful innovation to the movement disorder and epilepsy patient communities.”
